In Vitro Toxicity Testing Market By Type (Absorption, Toxic Substances, Dose), By Techniology (Cell Culture Technologies, High Throughput Technologies, Toxicogenomics), By End User (Cosmetics and Households Products, Pharmaceuticals Industry, Food Industr

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $3,961	231 Pages	Allied Market Research	March, 2022	ALMR17334406

Best Price Guarantee
Price	from $3,961
Length	231 Pages
Publisher	Allied Market Research
Published Date	March, 2022
SKU	ALMR17334406

In Vitro Toxicity Testing Market By Type (Absorption, Toxic Substances, Dose), By Techniology (Cell Culture Technologies, High Throughput Technologies, Toxicogenomics), By End User (Cosmetics and Households Products, Pharmaceuticals Industry, Food Industry, Chemicals Industry): Global Opportunity Analysis and Industry Forecast, 2020-2030

The global in vitro toxicity testing market was valued at $18,565.2 million in 2020 and is projected to reach $59,147.6 million by 2030, growing at a CAGR of 12.0% from 2020 to 2030.

In vitro is the process of performing experiments in a test tube, culture dish, or outside a living organism. In vitro toxicity testing (IVTT) examines the effects of toxic chemical substances on cultured bacteria. It is used to identify hazardous chemical substances and helps detect the toxicity at early stages of the development of new products, such as drugs, cosmetics, and food additives. It is majorly used for safety evaluation in drug development and for ranking the chemicals according to their potency. Moreover, absorption, distribution, metabolism, and excretion (ADME), dose response, and threshold response of drugs are determined by this method.

The growth of the global in vitro toxicity testing market is driven by increase in acceptance by regulatory authorities for using this method for testing. Moreover, ban on animal testing and increase in awareness towards environmental concerns boost the market growth. However, factors such as reduction in adoption rate of in vitro toxicity testing kits and incapability of in vitro models to determine autoimmunity & immunostimulation restrain the market growth. Conversely, rise in focus towards new approaches of 3D cell culture and advancement in genetics & genetic screening approaches are expected to provide potential opportunities for market expansion.

The in vitro toxicity testing market is segmented into type, technology, end users, and region. On the basis of type, the market is categorized into absorption, toxic substances, and dose. Currently, the absorption segment dominates the global in vitro toxicity testing market.

On the basis of end user, the market is categorized into pharmaceuticals, cosmetics & household products, chemicals industry, and food industry. The cosmetics and households products segment is dominant among end users, followed by the pharmaceutical industry. On the basis of technology, the in vitro toxicity testing market is segmented in to cell culture technologies, high throughput technologies, and toxicogenomics. The cell culture technologies segment generated the highest revenue in 2020.

On the basis of region, the in vitro toxicity testing market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America is the highest revenue growth, followed by Europe. LAMEA is predicted to grow faster than Asia-Pacific with a CAGR of 16.7% during the forecast period. The LAMEA segment is expected to dominate the in vitro toxicity testing market.

The key players operating in the market include, Acacia Pharma Group Plc., AstraZeneca Plc, GlaxoSmithKline Plc, Helsinn Holdings S.A., Heron Therapeutics Inc., Inc., General Electric Company, EISAI Pharmaceutical Pvt Ltd., Catalent, Inc., Laboratory Corporation of America Holdings., and Thermo Fisher Scientific, Inc.

Major players, such as GlaxoSmithKline Plc (GSK), General Electric Company, AstraZeneca Plc, and others are adopting the acquisition strategy to improve their product portfolio to maintain competition in the market. For instance, AstraZeneca completed the acquisition of Alexion pharmaceuticals, Inc. in July 2021. This acquisition aims to enhance scientific presence in immunology and through Alexion's innovative complement-biology platform and robust pipeline, and is expected to continue to pioneer the discovery and development of medicines for patients with rare diseases. Such instances are expected to provide lucrative opportunities for the major players for the growth of the market.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the in vitro toxicology industry segments, current trends, estimations, and dynamics of the in vitro toxicity testing market analysis from 2020 to 2030 to identify the prevailing in vitro toxicity testing market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the in vitro toxicity testing market segmentation, and in vitro toxicity testing market forecast assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global in vitro toxicity testing industry.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global in vitro toxicity testing market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

Absorption
Toxic Substances
Dose

By Techniology

Cell Culture Technologies
High Throughput Technologies
Toxicogenomics

By End User

Cosmetics and Households Products
Pharmaceuticals Industry
Food Industry
Chemicals Industry

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
Italy
France
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Rest Of Asia Pacific
LAMEA
Latin America
Middle East
Africa

Key Market Players

General Electric Company
Thermo Fisher Scientific, Inc.
Laboratory Corporation of America Holdings
ACACIA PHARMA GROUP PLC
TESARO INC.
Helsinn Holding S.A.
Heron Therapeutics Inc
AstraZeneca plc
Catalent Inc

CHAPTER 1:INTRODUCTION: 1.1.Report description; 1.2.Key market segments; 1.3.Key benefits to the stakeholders; 1.4.Research Methodology; 1.4.1.Secondary research; 1.4.2.Primary research; 1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY: 2.1.Key findings of the study; 2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW: 3.1.Market definition and scope; 3.2.Key findings; 3.2.1.Top investment pockets; 3.3.Porter’s five forces analysis; 3.4.Top player positioning; 3.5.Market dynamics; 3.5.1.Drivers; 3.5.2.Restraints; 3.5.3.Opportunities; 3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: IN VITRO TOXICITY TESTING MARKET, BY TYPE: 4.1 Overview; 4.1.1 Market size and forecast; 4.2 Absorption; 4.2.1 Key market trends, growth factors and opportunities; 4.2.2 Market size and forecast, by region; 4.2.3 Market analysis by country; 4.3 Toxic Substances; 4.3.1 Key market trends, growth factors and opportunities; 4.3.2 Market size and forecast, by region; 4.3.3 Market analysis by country; 4.4 Dose; 4.4.1 Key market trends, growth factors and opportunities; 4.4.2 Market size and forecast, by region; 4.4.3 Market analysis by country
CHAPTER 5: IN VITRO TOXICITY TESTING MARKET, BY TECHNIOLOGY: 5.1 Overview; 5.1.1 Market size and forecast; 5.2 Cell Culture Technologies; 5.2.1 Key market trends, growth factors and opportunities; 5.2.2 Market size and forecast, by region; 5.2.3 Market analysis by country; 5.3 High Throughput Technologies; 5.3.1 Key market trends, growth factors and opportunities; 5.3.2 Market size and forecast, by region; 5.3.3 Market analysis by country; 5.4 Toxicogenomics; 5.4.1 Key market trends, growth factors and opportunities; 5.4.2 Market size and forecast, by region; 5.4.3 Market analysis by country
CHAPTER 6: IN VITRO TOXICITY TESTING MARKET, BY END USER: 6.1 Overview; 6.1.1 Market size and forecast; 6.2 Cosmetics and Households Products; 6.2.1 Key market trends, growth factors and opportunities; 6.2.2 Market size and forecast, by region; 6.2.3 Market analysis by country; 6.3 Pharmaceuticals Industry; 6.3.1 Key market trends, growth factors and opportunities; 6.3.2 Market size and forecast, by region; 6.3.3 Market analysis by country; 6.4 Food Industry; 6.4.1 Key market trends, growth factors and opportunities; 6.4.2 Market size and forecast, by region; 6.4.3 Market analysis by country; 6.5 Chemicals Industry; 6.5.1 Key market trends, growth factors and opportunities; 6.5.2 Market size and forecast, by region; 6.5.3 Market analysis by country
CHAPTER 7: IN VITRO TOXICITY TESTING MARKET, BY REGION: 7.1 Overview; 7.1.1 Market size and forecast; 7.2 North America; 7.2.1 Key trends and opportunities; 7.2.2 North America Market size and forecast, by Type; 7.2.3 North America Market size and forecast, by Techniology; 7.2.4 North America Market size and forecast, by End User; 7.2.5 North America Market size and forecast, by country; 7.2.5.1 U.S.; 7.2.5.1.1 Market size and forecast, by Type; 7.2.5.1.2 Market size and forecast, by Techniology; 7.2.5.1.3 Market size and forecast, by End User; 7.2.5.2 Canada; 7.2.5.2.1 Market size and forecast, by Type; 7.2.5.2.2 Market size and forecast, by Techniology; 7.2.5.2.3 Market size and forecast, by End User; 7.2.5.3 Mexico; 7.2.5.3.1 Market size and forecast, by Type; 7.2.5.3.2 Market size and forecast, by Techniology; 7.2.5.3.3 Market size and forecast, by End User; 7.3 Europe; 7.3.1 Key trends and opportunities; 7.3.2 Europe Market size and forecast, by Type; 7.3.3 Europe Market size and forecast, by Techniology; 7.3.4 Europe Market size and forecast, by End User; 7.3.5 Europe Market size and forecast, by country; 7.3.5.1 Germany; 7.3.5.1.1 Market size and forecast, by Type; 7.3.5.1.2 Market size and forecast, by Techniology; 7.3.5.1.3 Market size and forecast, by End User; 7.3.5.2 Italy; 7.3.5.2.1 Market size and forecast, by Type; 7.3.5.2.2 Market size and forecast, by Techniology; 7.3.5.2.3 Market size and forecast, by End User; 7.3.5.3 France; 7.3.5.3.1 Market size and forecast, by Type; 7.3.5.3.2 Market size and forecast, by Techniology; 7.3.5.3.3 Market size and forecast, by End User; 7.3.5.4 Spain; 7.3.5.4.1 Market size and forecast, by Type; 7.3.5.4.2 Market size and forecast, by Techniology; 7.3.5.4.3 Market size and forecast, by End User; 7.3.5.5 Rest of Europe; 7.3.5.5.1 Market size and forecast, by Type; 7.3.5.5.2 Market size and forecast, by Techniology; 7.3.5.5.3 Market size and forecast, by End User; 7.4 Asia-Pacific; 7.4.1 Key trends and opportunities; 7.4.2 Asia-Pacific Market size and forecast, by Type; 7.4.3 Asia-Pacific Market size and forecast, by Techniology; 7.4.4 Asia-Pacific Market size and forecast, by End User; 7.4.5 Asia-Pacific Market size and forecast, by country; 7.4.5.1 China; 7.4.5.1.1 Market size and forecast, by Type; 7.4.5.1.2 Market size and forecast, by Techniology; 7.4.5.1.3 Market size and forecast, by End User; 7.4.5.2 Japan; 7.4.5.2.1 Market size and forecast, by Type; 7.4.5.2.2 Market size and forecast, by Techniology; 7.4.5.2.3 Market size and forecast, by End User; 7.4.5.3 India; 7.4.5.3.1 Market size and forecast, by Type; 7.4.5.3.2 Market size and forecast, by Techniology; 7.4.5.3.3 Market size and forecast, by End User; 7.4.5.4 South Korea; 7.4.5.4.1 Market size and forecast, by Type; 7.4.5.4.2 Market size and forecast, by Techniology; 7.4.5.4.3 Market size and forecast, by End User; 7.4.5.5 Rest Of Asia Pacific; 7.4.5.5.1 Market size and forecast, by Type; 7.4.5.5.2 Market size and forecast, by Techniology; 7.4.5.5.3 Market size and forecast, by End User; 7.5 LAMEA; 7.5.1 Key trends and opportunities; 7.5.2 LAMEA Market size and forecast, by Type; 7.5.3 LAMEA Market size and forecast, by Techniology; 7.5.4 LAMEA Market size and forecast, by End User; 7.5.5 LAMEA Market size and forecast, by country; 7.5.5.1 Latin America; 7.5.5.1.1 Market size and forecast, by Type; 7.5.5.1.2 Market size and forecast, by Techniology; 7.5.5.1.3 Market size and forecast, by End User; 7.5.5.2 Middle East; 7.5.5.2.1 Market size and forecast, by Type; 7.5.5.2.2 Market size and forecast, by Techniology; 7.5.5.2.3 Market size and forecast, by End User; 7.5.5.3 Africa; 7.5.5.3.1 Market size and forecast, by Type; 7.5.5.3.2 Market size and forecast, by Techniology; 7.5.5.3.3 Market size and forecast, by End User
CHAPTER 8: COMPANY LANDSCAPE: 8.1. Introduction; 8.2. Top winning strategies; 8.3. Product Mapping of Top 10 Player; 8.4. Competitive Dashboard; 8.5. Competitive Heatmap; 8.6. Key developments
CHAPTER 9: COMPANY PROFILES: 9.1 General Electric Company; 9.1.1 Company overview; 9.1.2 Company snapshot; 9.1.3 Operating business segments; 9.1.4 Product portfolio; 9.1.5 Business performance; 9.1.6 Key strategic moves and developments; 9.2 Thermo Fisher Scientific, Inc.; 9.2.1 Company overview; 9.2.2 Company snapshot; 9.2.3 Operating business segments; 9.2.4 Product portfolio; 9.2.5 Business performance; 9.2.6 Key strategic moves and developments; 9.3 Laboratory Corporation of America Holdings; 9.3.1 Company overview; 9.3.2 Company snapshot; 9.3.3 Operating business segments; 9.3.4 Product portfolio; 9.3.5 Business performance; 9.3.6 Key strategic moves and developments; 9.4 ACACIA PHARMA GROUP PLC; 9.4.1 Company overview; 9.4.2 Company snapshot; 9.4.3 Operating business segments; 9.4.4 Product portfolio; 9.4.5 Business performance; 9.4.6 Key strategic moves and developments; 9.5 TESARO INC.; 9.5.1 Company overview; 9.5.2 Company snapshot; 9.5.3 Operating business segments; 9.5.4 Product portfolio; 9.5.5 Business performance; 9.5.6 Key strategic moves and developments; 9.6 Helsinn Holding S.A.; 9.6.1 Company overview; 9.6.2 Company snapshot; 9.6.3 Operating business segments; 9.6.4 Product portfolio; 9.6.5 Business performance; 9.6.6 Key strategic moves and developments; 9.7 Heron Therapeutics Inc; 9.7.1 Company overview; 9.7.2 Company snapshot; 9.7.3 Operating business segments; 9.7.4 Product portfolio; 9.7.5 Business performance; 9.7.6 Key strategic moves and developments; 9.8 AstraZeneca plc; 9.8.1 Company overview; 9.8.2 Company snapshot; 9.8.3 Operating business segments; 9.8.4 Product portfolio; 9.8.5 Business performance; 9.8.6 Key strategic moves and developments; 9.9 Catalent Inc; 9.9.1 Company overview; 9.9.2 Company snapshot; 9.9.3 Operating business segments; 9.9.4 Product portfolio; 9.9.5 Business performance; 9.9.6 Key strategic moves and developments
LIST OF TABLES: TABLE 1. GLOBAL IN VITRO TOXICITY TESTING MARKET, BY TYPE, 2020-2030,($MILLION); TABLE 2. IN VITRO TOXICITY TESTING MARKET REVENUE, FOR ABSORPTION, BY REGION , 2020-2030,($MILLION); TABLE 3. IN VITRO TOXICITY TESTING MARKET ABSORPTION BY COUNTRY, 2020-2030,($MILLION); TABLE 4. IN VITRO TOXICITY TESTING MARKET REVENUE, FOR TOXIC SUBSTANCES, BY REGION , 2020-2030,($MILLION); TABLE 5. IN VITRO TOXICITY TESTING MARKET TOXIC SUBSTANCES BY COUNTRY, 2020-2030,($MILLION); TABLE 6. IN VITRO TOXICITY TESTING MARKET REVENUE, FOR DOSE, BY REGION , 2020-2030,($MILLION); TABLE 7. IN VITRO TOXICITY TESTING MARKET DOSE BY COUNTRY, 2020-2030,($MILLION); TABLE 8. GLOBAL IN VITRO TOXICITY TESTING MARKET, BY TECHNIOLOGY, 2020-2030,($MILLION); TABLE 9. IN VITRO TOXICITY TESTING MARKET REVENUE, FOR CELL CULTURE TECHNOLOGIES, BY REGION , 2020-2030,($MILLION); TABLE 10. IN VITRO TOXICITY TESTING MARKET CELL CULTURE TECHNOLOGIES BY COUNTRY, 2020-2030,($MILLION); TABLE 11. IN VITRO TOXICITY TESTING MARKET REVENUE, FOR HIGH THROUGHPUT TECHNOLOGIES, BY REGION , 2020-2030,($MILLION); TABLE 12. IN VITRO TOXICITY TESTING MARKET HIGH THROUGHPUT TECHNOLOGIES BY COUNTRY, 2020-2030,($MILLION); TABLE 13. IN VITRO TOXICITY TESTING MARKET REVENUE, FOR TOXICOGENOMICS, BY REGION , 2020-2030,($MILLION); TABLE 14. IN VITRO TOXICITY TESTING MARKET TOXICOGENOMICS BY COUNTRY, 2020-2030,($MILLION); TABLE 15. GLOBAL IN VITRO TOXICITY TESTING MARKET, BY END USER, 2020-2030,($MILLION); TABLE 16. IN VITRO TOXICITY TESTING MARKET REVENUE, FOR COSMETICS AND HOUSEHOLDS PRODUCTS, BY REGION , 2020-2030,($MILLION); TABLE 17. IN VITRO TOXICITY TESTING MARKET COSMETICS AND HOUSEHOLDS PRODUCTS BY COUNTRY, 2020-2030,($MILLION); TABLE 18. IN VITRO TOXICITY TESTING MARKET REVENUE, FOR PHARMACEUTICALS INDUSTRY, BY REGION , 2020-2030,($MILLION); TABLE 19. IN VITRO TOXICITY TESTING MARKET PHARMACEUTICALS INDUSTRY BY COUNTRY, 2020-2030,($MILLION); TABLE 20. IN VITRO TOXICITY TESTING MARKET REVENUE, FOR FOOD INDUSTRY, BY REGION , 2020-2030,($MILLION); TABLE 21. IN VITRO TOXICITY TESTING MARKET FOOD INDUSTRY BY COUNTRY, 2020-2030,($MILLION); TABLE 22. IN VITRO TOXICITY TESTING MARKET REVENUE, FOR CHEMICALS INDUSTRY, BY REGION , 2020-2030,($MILLION); TABLE 23. IN VITRO TOXICITY TESTING MARKET CHEMICALS INDUSTRY BY COUNTRY, 2020-2030,($MILLION); TABLE 24. IN VITRO TOXICITY TESTING MARKET, BY REGION, 2020-2030,($MILLION); TABLE 25. NORTH AMERICA IN VITRO TOXICITY TESTING MARKET, BY TYPE, 2020-2030,($MILLION); TABLE 26. NORTH AMERICA IN VITRO TOXICITY TESTING MARKET, BY TECHNIOLOGY, 2020-2030,($MILLION); TABLE 27. NORTH AMERICA IN VITRO TOXICITY TESTING MARKET, BY END USER, 2020-2030,($MILLION); TABLE 28. NORTH AMERICA IN VITRO TOXICITY TESTING MARKET, BY COUNTRY, 2020-2030,($MILLION); TABLE 29. U.S. IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION); TABLE 30. U.S. IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION); TABLE 31. U.S. IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION); TABLE 32. CANADA IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION); TABLE 33. CANADA IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION); TABLE 34. CANADA IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION); TABLE 35. MEXICO IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION); TABLE 36. MEXICO IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION); TABLE 37. MEXICO IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION); TABLE 38. EUROPE IN VITRO TOXICITY TESTING MARKET, BY TYPE, 2020-2030,($MILLION); TABLE 39. EUROPE IN VITRO TOXICITY TESTING MARKET, BY TECHNIOLOGY, 2020-2030,($MILLION); TABLE 40. EUROPE IN VITRO TOXICITY TESTING MARKET, BY END USER, 2020-2030,($MILLION); TABLE 41. EUROPE IN VITRO TOXICITY TESTING MARKET, BY COUNTRY, 2020-2030,($MILLION); TABLE 42. GERMANY IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION); TABLE 43. GERMANY IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION); TABLE 44. GERMANY IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION); TABLE 45. ITALY IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION); TABLE 46. ITALY IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION); TABLE 47. ITALY IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION); TABLE 48. FRANCE IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION); TABLE 49. FRANCE IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION); TABLE 50. FRANCE IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION); TABLE 51. SPAIN IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION); TABLE 52. SPAIN IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION); TABLE 53. SPAIN IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION); TABLE 54. REST OF EUROPE IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION); TABLE 55. REST OF EUROPE IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION); TABLE 56. REST OF EUROPE IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION); TABLE 57. ASIA-PACIFIC IN VITRO TOXICITY TESTING MARKET, BY TYPE, 2020-2030,($MILLION); TABLE 58. ASIA-PACIFIC IN VITRO TOXICITY TESTING MARKET, BY TECHNIOLOGY, 2020-2030,($MILLION); TABLE 59. ASIA-PACIFIC IN VITRO TOXICITY TESTING MARKET, BY END USER, 2020-2030,($MILLION); TABLE 60. ASIA-PACIFIC IN VITRO TOXICITY TESTING MARKET, BY COUNTRY, 2020-2030,($MILLION); TABLE 61. CHINA IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION); TABLE 62. CHINA IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION); TABLE 63. CHINA IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION); TABLE 64. JAPAN IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION); TABLE 65. JAPAN IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION); TABLE 66. JAPAN IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION); TABLE 67. INDIA IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION); TABLE 68. INDIA IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION); TABLE 69. INDIA IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION); TABLE 70. SOUTH KOREA IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION); TABLE 71. SOUTH KOREA IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION); TABLE 72. SOUTH KOREA IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION); TABLE 73. REST OF ASIA PACIFIC IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION); TABLE 74. REST OF ASIA PACIFIC IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION); TABLE 75. REST OF ASIA PACIFIC IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION); TABLE 76. LAMEA IN VITRO TOXICITY TESTING MARKET, BY TYPE, 2020-2030,($MILLION); TABLE 77. LAMEA IN VITRO TOXICITY TESTING MARKET, BY TECHNIOLOGY, 2020-2030,($MILLION); TABLE 78. LAMEA IN VITRO TOXICITY TESTING MARKET, BY END USER, 2020-2030,($MILLION); TABLE 79. LAMEA IN VITRO TOXICITY TESTING MARKET, BY COUNTRY, 2020-2030,($MILLION); TABLE 80. LATIN AMERICA IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION); TABLE 81. LATIN AMERICA IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION); TABLE 82. LATIN AMERICA IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION); TABLE 83. MIDDLE EAST IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION); TABLE 84. MIDDLE EAST IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION); TABLE 85. MIDDLE EAST IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION); TABLE 86. AFRICA IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION); TABLE 87. AFRICA IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION); TABLE 88. AFRICA IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION); TABLE 89.GENERAL ELECTRIC COMPANY: COMPANY SNAPSHOT; TABLE 90.GENERAL ELECTRIC COMPANY: OPERATING SEGMENTS; TABLE 91.GENERAL ELECTRIC COMPANY: PRODUCT PORTFOLIO; TABLE 92.GENERAL ELECTRIC COMPANY: NET SALES,; TABLE 93.GENERAL ELECTRIC COMPANY: KEY STRATERGIES; TABLE 94.THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT; TABLE 95.THERMO FISHER SCIENTIFIC, INC.: OPERATING SEGMENTS; TABLE 96.THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO; TABLE 97.THERMO FISHER SCIENTIFIC, INC.: NET SALES,; TABLE 98.THERMO FISHER SCIENTIFIC, INC.: KEY STRATERGIES; TABLE 99.LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT; TABLE 100.LABORATORY CORPORATION OF AMERICA HOLDINGS: OPERATING SEGMENTS; TABLE 101.LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT PORTFOLIO; TABLE 102.LABORATORY CORPORATION OF AMERICA HOLDINGS: NET SALES,; TABLE 103.LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY STRATERGIES; TABLE 104.ACACIA PHARMA GROUP PLC: COMPANY SNAPSHOT; TABLE 105.ACACIA PHARMA GROUP PLC: OPERATING SEGMENTS; TABLE 106.ACACIA PHARMA GROUP PLC: PRODUCT PORTFOLIO; TABLE 107.ACACIA PHARMA GROUP PLC: NET SALES,; TABLE 108.ACACIA PHARMA GROUP PLC: KEY STRATERGIES; TABLE 109.TESARO INC.: COMPANY SNAPSHOT; TABLE 110.TESARO INC.: OPERATING SEGMENTS; TABLE 111.TESARO INC.: PRODUCT PORTFOLIO; TABLE 112.TESARO INC.: NET SALES,; TABLE 113.TESARO INC.: KEY STRATERGIES; TABLE 114.HELSINN HOLDING S.A.: COMPANY SNAPSHOT; TABLE 115.HELSINN HOLDING S.A.: OPERATING SEGMENTS; TABLE 116.HELSINN HOLDING S.A.: PRODUCT PORTFOLIO; TABLE 117.HELSINN HOLDING S.A.: NET SALES,; TABLE 118.HELSINN HOLDING S.A.: KEY STRATERGIES; TABLE 119.HERON THERAPEUTICS INC: COMPANY SNAPSHOT; TABLE 120.HERON THERAPEUTICS INC: OPERATING SEGMENTS; TABLE 121.HERON THERAPEUTICS INC: PRODUCT PORTFOLIO; TABLE 122.HERON THERAPEUTICS INC: NET SALES,; TABLE 123.HERON THERAPEUTICS INC: KEY STRATERGIES; TABLE 124.ASTRAZENECA PLC: COMPANY SNAPSHOT; TABLE 125.ASTRAZENECA PLC: OPERATING SEGMENTS; TABLE 126.ASTRAZENECA PLC: PRODUCT PORTFOLIO; TABLE 127.ASTRAZENECA PLC: NET SALES,; TABLE 128.ASTRAZENECA PLC: KEY STRATERGIES; TABLE 129.CATALENT INC: COMPANY SNAPSHOT; TABLE 130.CATALENT INC: OPERATING SEGMENTS; TABLE 131.CATALENT INC: PRODUCT PORTFOLIO; TABLE 132.CATALENT INC: NET SALES,; TABLE 133.CATALENT INC: KEY STRATERGIES
LIST OF FIGURES: FIGURE 1.IN VITRO TOXICITY TESTING MARKET SEGMENTATION; FIGURE 2.IN VITRO TOXICITY TESTING MARKET,2020-2030; FIGURE 3.IN VITRO TOXICITY TESTING MARKET,2020-2030; FIGURE 4. TOP INVESTMENT POCKETS, BY REGION; FIGURE 5.PORTER FIVE-1; FIGURE 6.PORTER FIVE-2; FIGURE 7.PORTER FIVE-3; FIGURE 8.PORTER FIVE-4; FIGURE 9.PORTER FIVE-5; FIGURE 10.TOP PLAYER POSITIONING; FIGURE 11.IN VITRO TOXICITY TESTING MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES; FIGURE 11.IN VITRO TOXICITY TESTING MARKET,BY TYPE,2020(%); FIGURE 12.COMPARATIVE SHARE ANALYSIS OF ABSORPTION IN VITRO TOXICITY TESTING MARKET,2020-2030(%); FIGURE 13.COMPARATIVE SHARE ANALYSIS OF TOXIC SUBSTANCES IN VITRO TOXICITY TESTING MARKET,2020-2030(%); FIGURE 14.COMPARATIVE SHARE ANALYSIS OF DOSE IN VITRO TOXICITY TESTING MARKET,2020-2030(%); FIGURE 15.IN VITRO TOXICITY TESTING MARKET,BY TECHNIOLOGY,2020(%); FIGURE 16.COMPARATIVE SHARE ANALYSIS OF CELL CULTURE TECHNOLOGIES IN VITRO TOXICITY TESTING MARKET,2020-2030(%); FIGURE 17.COMPARATIVE SHARE ANALYSIS OF HIGH THROUGHPUT TECHNOLOGIES IN VITRO TOXICITY TESTING MARKET,2020-2030(%); FIGURE 18.COMPARATIVE SHARE ANALYSIS OF TOXICOGENOMICS IN VITRO TOXICITY TESTING MARKET,2020-2030(%); FIGURE 19.IN VITRO TOXICITY TESTING MARKET,BY END USER,2020(%); FIGURE 20.COMPARATIVE SHARE ANALYSIS OF COSMETICS AND HOUSEHOLDS PRODUCTS IN VITRO TOXICITY TESTING MARKET,2020-2030(%); FIGURE 21.COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICALS INDUSTRY IN VITRO TOXICITY TESTING MARKET,2020-2030(%); FIGURE 22.COMPARATIVE SHARE ANALYSIS OF FOOD INDUSTRY IN VITRO TOXICITY TESTING MARKET,2020-2030(%); FIGURE 23.COMPARATIVE SHARE ANALYSIS OF CHEMICALS INDUSTRY IN VITRO TOXICITY TESTING MARKET,2020-2030(%); FIGURE 24.IN VITRO TOXICITY TESTING MARKET BY REGION,2020; FIGURE 25.U.S. IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION); FIGURE 26.CANADA IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION); FIGURE 27.MEXICO IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION); FIGURE 28.GERMANY IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION); FIGURE 29.ITALY IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION); FIGURE 30.FRANCE IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION); FIGURE 31.SPAIN IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION); FIGURE 32.REST OF EUROPE IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION); FIGURE 33.CHINA IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION); FIGURE 34.JAPAN IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION); FIGURE 35.INDIA IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION); FIGURE 36.SOUTH KOREA IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION); FIGURE 37.REST OF ASIA PACIFIC IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION); FIGURE 38.LATIN AMERICA IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION); FIGURE 39.MIDDLE EAST IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION); FIGURE 40.AFRICA IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION); FIGURE 41. TOP WINNING STRATEGIES, BY YEAR; FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT; FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY; FIGURE 44.PRODUCT MAPPING OF TOP 10 PLAYERS; FIGURE 45.COMPETITIVE DASHBOARD; FIGURE 46.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS; FIGURE 47.GENERAL ELECTRIC COMPANY.: NET SALES ,($MILLION); FIGURE 48.THERMO FISHER SCIENTIFIC, INC..: NET SALES ,($MILLION); FIGURE 49.LABORATORY CORPORATION OF AMERICA HOLDINGS.: NET SALES ,($MILLION); FIGURE 50.ACACIA PHARMA GROUP PLC.: NET SALES ,($MILLION); FIGURE 51.TESARO INC..: NET SALES ,($MILLION); FIGURE 52.HELSINN HOLDING S.A..: NET SALES ,($MILLION); FIGURE 53.HERON THERAPEUTICS INC.: NET SALES ,($MILLION); FIGURE 54.ASTRAZENECA PLC.: NET SALES ,($MILLION); FIGURE 55.CATALENT INC.: NET SALES ,($MILLION)